Table 2.
Baseline characteristics of 1227 patients who underwent resection for hepatocellular carcinoma with regular follow-up stratified by risk of recurrence and follow-up interval
| Characteristics | Low-risk patients | High-risk patients | ||||
|---|---|---|---|---|---|---|
| Long interval | Short interval | P | Long interval | Short interval | P | |
| (n = 390) | (n = 475) (%) | (n = 149) (%) | (n = 213) (%) | |||
| Gender | 0.926 | 0.001 | ||||
| Male | 344 (88.2) | 418 (88) | 123 (82.6) | 199 (93.4) | ||
| Female | 46 (11.8) | 57 (12.0) | 26 (17.4) | 14 (6.6) | ||
| Age (years) | 52 (14) | 50 (19) | 0.072 | 51 (17) | 49 (17) | 0.292 |
| Tumor number | 0.273 | 0.891 | ||||
| Solitary | 359 (92.1) | 427 (89.9) | 92 (61.7) | 130 (61) | ||
| Multiple | 31 (7.9) | 48 (10.1) | 57 (38.3) | 83 (39) | ||
| Tumor size (cm) | 0.458 | 0.674 | ||||
| > 5 | 60 (15.4) | 82 (17.3) | 109 (73.2) | 160 (75.1) | ||
| ≤ 5 | 330 (84.6) | 393 (82.7) | 40 (26.8) | 53 (24.9) | ||
| Tumor size (cm) | 3.5 (2.0) | 3.5 (2.3) | 0.288 | 8 (5.0) | 8 (4.8) | 0.916 |
| Tumor location | 0.054 | 0.287 | ||||
| Central | 96 (24.6) | 145 (30.5) | 16 (10.7) | 16 (7.5) | ||
| Subcapsular | 294 (75.4) | 330 (69.5) | 133 (89.3) | 197 (92.5) | ||
| Tumor differentiation | 0.393 | 0.761 | ||||
| Poor | 45 (11.5) | 64 (13.5) | 20 (13.4) | 31 (14.6) | ||
| Moderate and well | 345 (88.5) | 411 (86.5) | 129 (86.6) | 182 (85.4) | ||
| Tumor MVI | 0.627 | 0.126 | ||||
| Yes | 27 (6.9) | 29 (6.1) | 95 (63.8) | 152 (71.4) | ||
| No | 363 (93.1) | 446 (93.9) | 54 (36.2) | 61 (28.6) | ||
| BCLC stage | 0.604 | 0.238 | ||||
| 0/A | 380 (97.4) | 460 (96.8) | 110 (73.8) | 145 (68.1) | ||
| B | 10 (2.6) | 15 (3.2) | 39 (26.2) | 68 (31.9) | ||
| Etiology | 0.901 | 0.694 | ||||
| Non-hepatitis | 37 (9.5) | 47 (9.9) | 18 (12.1) | 22 (10.3) | ||
| HBV | 347 (89) | 420 (88.4) | 129 (86.6) | 189 (88.7) | ||
| HCV | 6 (1.5) | 8 (1.7) | 2 (1.3) | 2 (0.9) | ||
| WBC (109/L) | 5.8 (1.9) | 5.9 (2.3) | 0.189 | 6.0 (2) | 6.5 (2.8) | 0.014 |
| RBC (109/L) | 4.73 (0.7) | 4.8 (0.7) | 0.123 | 4.75 (0.7) | 4.81 (0.7) | 0.460 |
| Hemoglobin (g/L) | 147 (16.4) | 146.7 (18) | 0.922 | 144 (22) | 145.9 (20.9) | 0.392 |
| PLT (109/L) | 161.3 (79.3) | 162 (72) | 0.526 | 192 (88) | 189 (77) | 0.643 |
| ALT (U/L) | 36.9 (27.2) | 36.1 (23.7) | 0.857 | 37 (26.7) | 39.8 (29.6) | 0.196 |
| AST (U/L) | 31.2 (16.8) | 31.5 (14.8) | 0.882 | 39.4 (25.4) | 40.7 (25.2) | 0.774 |
| ALB (g/L) | 42.8 (4.6) | 43.1 (4.5) | 0.083 | 42.2 (4.7) | 43 (4.4) | 0.074 |
| TBIL (μmol/L) | 12.9 (5.9) | 13.4 (6.5) | 0.129 | 12.2 (6.2) | 12.7 (5.8) | 0.502 |
| PT (s) | 11.7 (1.3) | 11.6 (1.2) | 0.590 | 11.6 (1.2) | 11.6 (1.1) | 0.615 |
| ALBI grade | 0.720 | 0.432 | ||||
| I | 335 (85.9) | 412 (86.7) | 116 (77.9) | 173 (81.2) | ||
| II | 55 (14.1) | 63 (13.3) | 33 (22.1) | 40 (18.8) | ||
| AFP (ng/mL) | 0.289 | 0.905 | ||||
| > 200 | 111 (28.5) | 151 (31.8) | 66 (44.3) | 93 (43.7) | ||
| ≤ 200 | 279 (71.5) | 324 (68.2) | 83 (55.7) | 120 (56.3) | ||
| Cirrhosis | 0.957 | 0.296 | ||||
| Yes | 288 (73.8) | 350 (73.7) | 95 (63.8) | 147 (69) | ||
| No | 102 (26.2) | 125 (26.3) | 54 (36.2) | 66 (31) | ||
| Resection margin (cm) | 1 (1.5) | 1 (1.15) | 0.526 | 1 (1.5) | 1 (1.5) | 0.894 |
| Operative blood loss (ml) | 0.691 | 0.173 | ||||
| > 400 | 45 (11.5) | 59 (12.4) | 52 (34.9) | 60 (28.2) | ||
| ≤ 400 | 345 (88.5) | 416 (87.6) | 97 (65.1) | 153 (71.8) | ||
Values are presented as the median (interquartile range) or n (%)
MVI microvascular invasion, BCLC stage Barcelona clinic liver cancer stage, HBV hepatitis B virus, HCV hepatitis C virus, WBC white blood cell, RBC red blood cell, PLT platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, TBIL total bilirubin, PT prothrombin time, ALBI albumin-bilirubin, AFP alpha-fetoprotein